RAD51C and cancer: Pathogenic variants in BRCA2/FANCD1, PALB2/FANCN, BRIP1/FANCJ, and RAD51C/FANCO have known adult-onset cancer risks, and there are recommendations for carriers to have increased cancer surveillance, consider chemoprevention, or undergo preventative surgeries (45).